Efficacy and Safety of Dual Paclitaxel and Sirolimus Nanoparticle-Coated Balloon.
JACC Basic Transl Sci
; 9(6): 774-789, 2024 Jun.
Article
in En
| MEDLINE
| ID: mdl-39070273
ABSTRACT
We evaluated a novel dual active pharmaceutical ingredient (API) drug-coated balloon (DCB), which consists of a coating of nanoparticles encapsulating low-dose paclitaxel (PTX) in combination with sirolimus in a synergistic ratio. Compared to the PTX DCB, the dual API DCB demonstrated similar inhibition of cell proliferation in vitro but at a significantly lower total drug dose (over 13 times lower than sirolimus nanoparticles). Animal experiments demonstrated that the dual API DCB is more effective in inhibiting intimal cell proliferation with insignificant downstream embolic effects and myocardial damage compared to the PTX DCB. These findings indicate that dual API DCBs have a high potential to demonstrate improved clinical outcomes and a greater safety profile than the PTX DCBs.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
JACC Basic Transl Sci
Year:
2024
Document type:
Article
Affiliation country:
United States
Country of publication:
United States